Yuichiro Mita
Doshisha University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yuichiro Mita.
Journal of Neuropathology and Experimental Neurology | 2014
Yoshiro Saito; Tomohiro Miyasaka; Hiroyuki Hatsuta; Kazuko Takahashi-Niki; Kojiro Hayashi; Yuichiro Mita; Osamu Kusano-Arai; Hiroko Iwanari; Hiroyoshi Ariga; Takao Hamakubo; Yasukazu Yoshida; Etsuo Niki; Shigeo Murayama; Yasuo Ihara; Noriko Noguchi
Supplemental digital content is available in the text.
Scientific Reports | 2016
Yoshiro Saito; Yoko Akazawa-Ogawa; Akihiro Matsumura; Kazumasa Saigoh; Sayoko Itoh; Kenta Sutou; Mayuka Kobayashi; Yuichiro Mita; Mototada Shichiri; Shin Hisahara; Yasuo Hara; Harutoshi Fujimura; Hiroyuki Takamatsu; Yoshihisa Hagihara; Yasukazu Yoshida; Takao Hamakubo; Susumu Kusunoki; Shun Shimohama; Noriko Noguchi
Parkinson’s disease (PD) is a progressive, age-related, neurodegenerative disorder, and oxidative stress is an important mediator in its pathogenesis. DJ-1, the product of the causative gene of a familial form of PD, plays a significant role in anti-oxidative defence to protect cells from oxidative stress. DJ-1 undergoes preferential oxidation at the cysteine residue at position 106 (Cys-106) under oxidative stress. Here, using specific antibodies against Cys-106-oxidized DJ-1 (oxDJ-1), it was found that the levels of oxDJ-1 in the erythrocytes of unmedicated PD patients (n = 88) were higher than in those of medicated PD patients (n = 62) and healthy control subjects (n = 33). Elevated oxDJ-1 levels were also observed in a non-human primate PD model. Biochemical analysis of oxDJ-1 in erythrocyte lysates showed that oxDJ-1 formed dimer and polymer forms, and that the latter interacts with 20S proteasome. These results clearly indicate a biochemical alteration in the blood of PD patients, which could be utilized as an early diagnosis marker for PD.
Nature Communications | 2017
Yuichiro Mita; Kaho Nakayama; Shogo Inari; Yukina Nishito; Yuya Yoshioka; Naoko Sakai; Kanade Sotani; Takahiro Nagamura; Yuki Kuzuhara; Kumi Inagaki; Miki Iwasaki; Hirofumi Misu; Masaya Ikegawa; Toshinari Takamura; Noriko Noguchi; Yoshiro Saito
Selenoprotein P (SeP) functions as a selenium (Se)-supply protein. SeP is identified as a hepatokine, promoting insulin resistance in type 2 diabetes. Thus, the suppression of Se-supply activity of SeP might improve glucose metabolism. Here, we develop an anti-human SeP monoclonal antibody AE2 as with neutralizing activity against SeP. Administration of AE2 to mice significantly improves glucose intolerance and insulin resistance that are induced by human SeP administration. Furthermore, excess SeP administration significantly decreases pancreas insulin levels and high glucose-induced insulin secretion, which are improved by AE2 administration. Epitope mapping reveals that AE2 recognizes a region of human SeP adjacent to the first histidine-rich region (FHR). A polyclonal antibody against the mouse SeP FHR improves glucose intolerance and insulin secretion in a mouse model of diabetes. This report describes a novel molecular strategy for the development of type 2 diabetes therapeutics targeting SeP.Selenoprotein P is secreted by the liver and when present in excess it promotes development of type 2 diabetes. Here the authors develop neutralizing antibodies to target human and mouse selenoprotein P, and show that they improve insulin secretion and glucose tolerance in mouse models.
Journal of Lipid Research | 2015
Yoshiro Saito; Mototada Shichiri; Takashi Hamajima; Noriko Ishida; Yuichiro Mita; Shohei Nakao; Yoshihisa Hagihara; Yasukazu Yoshida; Kazuhiko Takahashi; Etsuo Niki; Noriko Noguchi
Selenocysteine (Sec) insertion sequence-binding protein 2 (SBP2) is essential for the biosynthesis of Sec-containing proteins, termed selenoproteins. Subjects with mutations in the SBP2 gene have decreased levels of several selenoproteins, resulting in a complex phenotype. Selenoproteins play a significant role in antioxidative defense, and deficiencies in these proteins can lead to increased oxidative stress. However, lipid peroxidation and the effects of antioxidants in subjects with SBP2 gene mutations have not been studied. In the present study, we evaluated the lipid peroxidation products in the blood of a subject (the proband) with mutations in the SBP2 gene. We found that the proband had higher levels of free radical-mediated lipid peroxidation products, such as 7β-hydroxycholesterol, than the control subjects. Treatment of the proband with vitamin E (α-tocopherol acetate, 100 mg/day), a lipid-soluble antioxidant, for 2 years reduced lipid peroxidation product levels to those of control subjects. Withdrawal of vitamin E treatment for 7 months resulted in an increase in lipid peroxidation products. Collectively, these results clearly indicate that free radical-mediated oxidative stress is increased in the subject with SBP2 gene mutations and that vitamin E treatment effectively inhibits the generation of lipid peroxidation products.
Scientific Reports | 2018
Yuichiro Mita; Yuto Kataoka; Yoshiro Saito; Takuma Kashi; Kojiro Hayashi; Asa Iwasaki; Takanori Imanishi; Tomohiro Miyasaka; Noriko Noguchi
DJ-1 plays an important role in antioxidant defenses, and a reactive cysteine at position 106 (Cys106) of DJ-1, a critical residue of its biological function, is oxidized under oxidative stress. DJ-1 oxidation has been reported in patients with Parkinson’s disease (PD), but the relationship between DJ-1 oxidation and PD is still unclear. In the present study using specific antibody for Cys106-oxidized DJ-1 (oxDJ-1), we analyzed oxDJ-1 levels in the brain and peripheral tissues in young and aged mice and in a mouse model of PD induced using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). OxDJ-1 levels in the brain, heart, and skeletal muscle were high compared with other tissues. In the brain, oxDJ-1 was detected in PD-related brain sites such as the substantia nigra (SN) of the midbrain, olfactory bulb (OB), and striatum. In aged wild-type mice, oxDJ-1 levels in the OB, striatum, and heart tended to decrease, while those in the skeletal muscle increased significantly. Expression of dopamine-metabolizing enzymes significantly increased in the SN and OB of aged DJ-1−/− mice, accompanied by a complementary increase in glutathione peroxidase 1. MPTP treatment concordantly changed oxDJ-1 levels in PD-related brain sites and heart. These results indicate that the effects of physiological metabolism, aging, and neurotoxin change oxDJ-1 levels in PD-related brain sites, heart, and skeletal muscle where mitochondrial load is high, suggesting a substantial role of DJ-1 in antioxidant defenses and/or dopamine metabolism in these tissues.
Nature Medicine | 2017
Hirofumi Misu; Hiroaki Takayama; Yoshiro Saito; Yuichiro Mita; Akihiro Kikuchi; Kiyoaki Ishii; Keita Chikamoto; Takehiro Kanamori; Natsumi Tajima; Fei Lan; Yumie Takeshita; Masao Honda; Mutsumi Tanaka; Seiji Kato; Naoto Matsuyama; Yuya Yoshioka; Kaito Iwayama; Nobuhiko Akazawa; Seiji Maeda; Kazuhiro Takekoshi; Seiichi Matsugo; Noriko Noguchi; Shuichi Kaneko; Toshinari Takamura
Free Radical Biology and Medicine | 2018
Yoshiro Saito; Yuichiro Mita; Shogo Inari; Takahiro Nagamura; Hirofumi Misu; Toshinari Takamura; Noriko Noguchi
The Japanese Biochemical Society/The Molecular Biology Society of Japan | 2017
Risa Uchida; Yuichiro Mita; Tadashi Yokooji; Sayuri Yasuhara; Yoshiro Saito; Noriko Noguchi
The Japanese Biochemical Society/The Molecular Biology Society of Japan | 2017
Yuichiro Mita; Yoshiro Saito; Risa Uchida; Sayuri Yasuhara; Sho Yokooji; Noriko Noguchi
The Japanese Biochemical Society/The Molecular Biology Society of Japan | 2017
Shohei Nakao; Yuichiro Mita; Yoshiro Saito; Noriko Noguchi
Collaboration
Dive into the Yuichiro Mita's collaboration.
National Institute of Advanced Industrial Science and Technology
View shared research outputs